ASM/BMI

1. ASM/BMI decreases systolic blood pressure in humans (β = − 39.35).

   “ASM/BMI was significantly negatively correlated with systolic blood pressure (β = − 39.35)”

   Humansolder diabetic patients

   Association of Obesity and Sarcopenia with Cardiometabolic Outcomes in Older Adults and Sex-Modified Effects: A Study Based on CHARLS

   Research Square·1 Sep 2026Preprint

More on Systolic blood pressure

1. ASM/BMI is associated with gait speed in humans (standardized β=0.122, p<0.001).

   “ASM/BMI was positively associated with gait speed (standardized β=0.122, p<0.001).”

   Humanscommunity-dwelling older adultsn = 8,073

   Clinical Implications of the AWGS 2025 Sarcopenia Criteria in a Large Cohort of Community-Dwelling Thai Older Adults

   Annals of geriatric medicine and research·24 Aug 2026

1. ASM/BMI lowers the risk of alcohol-associated liver disease in humans (RR 0.40, 95% CI 0.18-0.88).

   “and between ALD and ASM/BMI (0.40, 0.18-0.88).”

   Humans4.3 yearsn = 1,964

   Effects of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease—Findings from a Prospective Cohort Study in China

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Alcohol-associated liver disease

1. ASM/BMI lowers the risk of metabolic dysfunction-associated steatotic liver disease in humans (RR 0.51, 95% CI 0.40-0.64).

   “0.51, 0.40-0.64).”

   Humans4.3 yearsn = 1,964

   Effects of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease—Findings from a Prospective Cohort Study in China

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Metabolic dysfunction-associated steatotic liver disease